



## KILPEST INDIA LIMITED

#### REGD. OFFICE & FACTORY:

7-C, INDUSTRIAL AREA, GOVINDPURA, BHOPAL - 462 023 (INDIA)

Tel : (91-755) 2586536, 2586537

FAX NO.: (91-755) 2580438 Email: kilpest@bsnl.in

kilpestbpl@yahoo.co.in

visit us at: www.kilpest.com CIN: L24211MP1972PLC001131

Date: 29-07-2019

The General Manager, Department of Corporate Services, BSE Limited, P. J Tower, Dalal Street, Fort Mumbai- 400023

### SUB- Statement of deviation or variation under Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

The Company has issue and allotted 11,00, 000 Equity shares pursuant to conversion of share warrants to Non-Promoters and on a preferential basis on 18th December 2017 .

As required under Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby state that the Audit Committee at its meeting held on 29<sup>th</sup> July 2019 has reviewed the utilization of funds received and there has been no deviation or variation in the utilization of the issue proceeds as mentioned above and has been utilized for the purpose for which they were raised.

Therefore, we hereby submit the Statement of Deviation or Variation for our proposed Preferential Issue of the Company.

- i) Deviation, if any in the use of proceeds from the object stated in the offer documents.
- There is no deviation in the use of proceeds from the object stated in the offer documents.
- ii) Category wise variation between projected utilization of funds made in offer document and the actual utilization of funds are as follow:

Sr. No.	Particulars	Projected utilization of funds as per offer document (Rs in lakh)	Actual utilization of funds till 30 <sup>th</sup> june, 2019(Rs in lakh)
1	Pay off Debt with aim to make Company "Zero Debt" in future.		388.03
2	Infuse funds in Subsidiary to accelerate growth of M/s 3B BlackBio Biotech India Limited, Subsidiary Company	935.00	300.00
3	Upgrade R&D, Formulation plants of the Company		Nil
4	Use funds in working capital requirement.		246.97
	TOTAL	935.00	935.00

This is for your information, action and record please.

Thanking You, For Kilpest India Limited

Dhirendra Dubey Director



# CA

#### BAHETI & CO.

CHARTERED ACCOUNTANTS
24,M.P. NAGAR ZONE II
BHOPAL 462011
2763141,4251535

To, KILPEST INDIA LIMITED 7-C, INDUSTRIAL AREA BHOPAL (MP)

Subject: Statement of Deviation or Variation under Regulation 32 of SEBI [Listing Obligations and Disclosure Requirements) Regulations. 2015.

This is to bring to your notice that in accordance with the Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we have hereby certified the Statement of Deviation or Variation for the Preferential Issue of 11,00,000 Equity Shares of KILPEST INDIA LIMITED

- Deviation, if any in the use of proceeds from the objects stated in the offer document or explanatory statement to the notice for the General Meeting, as applicable.
   There is no deviation in the use of proceeds from the object stated in the offer document.
- 2. Category-wise variation between projected utilization of funds made in the offer document or explanatory statement to the notice for the general meeting, as applicable and the actual utilization of funds are as follows:

Sr. No.	Particulars	Projected utilization of funds as per offer document (Rs in lakh)	Actual utilization of funds till 30 <sup>th</sup> june, 2019(Rs in lakh)
1	Pay off Debt with aim to make Company "Zero Debt" in future.		388.03
2	Infuse funds in Subsidiary to accelerate growth of M/s 3B BlackBio Biotech India Limited, Subsidiary Company	935.00	300.00
3	Upgrade R&D, Formulation plants of the Company		Nil
4	Use funds in working capital requirement.		246.97
	TOTAL	935.00	935.00

For BAHETI & CO.

Chartered Accountants

Firm's registration No: 006287C

Deepak Baheti

PARTNER

Membership No: 075063

Date: 29.07.2019

UDIN 19075063 AAAAFA 2740